Clinical study on significant antihypertensive effects of two Rg3 enriched Korean ginsengs

Clinical study on significant antihypertensive effects of two Rg3 enriched Korean ginsengs (vitamin C-treated white ginseng and enzyme-treated red ginseng) on moderate hypertensive subject: Randomized, double-blind, placebo-controlled, and long-term human trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0008475

Enrollment

Registered

2023-05-26

Start date

2020-11-09

Completion date

Unknown

Last updated

2023-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : In this study, 12 weeks, randomized, double-blind, and placebo-controlled clinical trial was conducted to evaluate the efficacy and safety of Rg3-enriched Korean ginsengs for mode

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Men and women aged between 20 and 70 years. 2. Participants for whom after resting 5 min in a sitting position, the average SBP measured twice with a 2-minute interval was 125-245 mmHg, or the DBP was in the range of 80-95 mmHg, except for those who required medication. For those with stage 1 hypertension, the SBP range was 140-145 mmHg or the DBP was 90-95 mmHg. 3. People who voluntarily decided to participate and agreed in writing to abide by the precautions after hearing and fully understanding the detailed explanation of this study.

Exclusion criteria

Exclusion criteria: 1. Participants having a history of hypersensitivity and a habit of ginseng and red ginseng consumption. 2. Those who have taken blood pressure-lowering drugs or blood circulation improving drugs (ginkgo leaf extract, aspirin, etc.). 3. Participants who have taken herbal medicines, peptides-containing medicines/food, oral steroids, or hormones within the last one month. 4. Participants who are under treatment for alcoholism or being treated for thyroid dysfunction. 5. Diabetic patients who are currently taking medications. 6. Those who underwent surgery within the last six months. 7. People having severe renal or hepatic dysfunction. 8. Those who have had surgery that may affect drug absorption, such as gastrectomy. 9. Pregnant, lactating, and childbearing women who do not use appropriate contraceptive methods. 10. Those who have consumed other clinical trial foods or test drugs within the last two months. 11. Those who have donated blood within the last two months. 12. Patients with uncontrolled hypertension (160/100 mmHg) or those who are taking new medications due to high blood pressure within the last three months.

Design outcomes

Primary

Measure	Time frame
Determined based on the systolic blood pressure (SBP), and the diastolic blood pressure (DBP)	—

Secondary

Measure	Time frame
mean arterial blood pressure (MBP) and average pulse, NO production in blood, and highly sensitive C-reactive protein (hs-CRP)	—

Countries

Korea, Republic of

Contacts

Public ContactSeong Lee

Dankook Univeristy Hospital

seonglee@empas.com+82-41-550-7491

Outcome results